You just read:

European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids

News provided by

European Hematology Association

24 Jun, 2017, 07:30 BST